| Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma (NCT04792502) | Brown University | 2022-07-14 |
| Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion (NCT05385263) | Tel-Aviv Sourasky Medical Center | 2022-05-11 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809) | John Lister | 2022-04-19 |
| Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART (NCT05286164) | Tel-Aviv Sourasky Medical Center | 2022-04-01 |
| Long-Term Follow-up Study (NCT05332054) | Caribou Biosciences, Inc. | 2022-03-16 |
| CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia (NCT06081478) | Beijing Tongren Hospital | 2022-01-18 |
| A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas (NCT05113069) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-12-22 |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (NCT04599634) | National Cancer Institute (NCI) | 2021-12-16 |
| Natural Killer (NK) Cell Therapy for B-Cell Malignancies (NCT05379647) | Zhejiang University | 2021-11-04 |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (NCT05024045) | Eli Lilly and Company | 2021-09-30 |
| Venetoclax Plus Inotuzumab for B-ALL (NCT05016947) | Dana-Farber Cancer Institute | 2021-09-24 |
| Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma (NCT05014100) | Puyang Oilfield General Hospital | 2021-09-01 |
| UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies (NCT05015972) | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2021-08-20 |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (NCT04491370) | New York Medical College | 2021-08-01 |
| A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma (NCT04993690) | Guangzhou Lupeng Pharmaceutical Company LTD. | 2021-07-06 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (NCT04637763) | Caribou Biosciences, Inc. | 2021-05-26 |
| a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (NCT04782193) | Chongqing Precision Biotech Co., Ltd | 2021-05-23 |
| CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL (NCT04877080) | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2021-05-05 |
| Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers (NCT04804254) | AbbVie | 2021-04-27 |
| Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors (NCT04814004) | Kai Lin Xu; Jun Nian Zheng | 2021-03-19 |
| Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies (NCT04796688) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-03-10 |
| Induced-T Cell Like NK Cells for B Cell Malignancies (NCT04747093) | Nanfang Hospital, Southern Medical University | 2021-01-29 |
| Clinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin Lymphoma (NCT04641806) | Versailles Hospital | 2020-11-01 |
| Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA (NCT04539119) | Ruijin Hospital | 2020-07-03 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 (NCT04418141) | Curon Biopharmaceutical (Australia) Co Pty Ltd | 2020-07-02 |
| A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma (NCT04313608) | Hoffmann-La Roche | 2020-06-04 |
| CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies (NCT04605666) | Nanfang Hospital, Southern Medical University | 2020-05-01 |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) (NCT04018248) | Boryung Pharmaceutical Co., Ltd | 2020-04-21 |
| Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia (NCT04289220) | Yan'an Affiliated Hospital of Kunming Medical University | 2020-03-15 |
| PD1-CD19-CART in Patients With r/r B-cell Lymphoma (NCT04213469) | Bioray Laboratories | 2020-03-13 |
| CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (NCT04260932) | Hebei Yanda Ludaopei Hospital | 2020-03-01 |
| CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (NCT04088864) | Kara Lynn Davis | 2020-01-10 |
| A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy (NCT04148430) | Memorial Sloan Kettering Cancer Center | 2019-10-30 |
| FT516 in Subjects With Advanced Hematologic Malignancies (NCT04023071) | Fate Therapeutics | 2019-10-04 |
| Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma (NCT03995147) | University of Chicago | 2019-08-29 |
| A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy (NCT04036019) | Shanghai Tongji Hospital, Tongji University School of Medicine | 2019-08-20 |
| Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies (NCT04007978) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-08-05 |
| A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) (NCT04035434) | CRISPR Therapeutics AG | 2019-07-22 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT04045028) | Genentech, Inc. | 2019-07-22 |
| Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (NCT04008251) | Wuhan Sian Medical Technology Co., Ltd | 2019-05-27 |
| Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. (NCT03929107) | Wenbin Qian | 2019-03-28 |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (NCT03740529) | Loxo Oncology, Inc. | 2019-03-15 |
| Study of TG-1801 in Subjects With B-Cell Lymphoma (NCT03804996) | TG Therapeutics, Inc. | 2019-03-05 |
| Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies (NCT03881774) | Henan Cancer Hospital | 2019-02-27 |
| Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (NCT03761056) | Kite, A Gilead Company | 2019-01-29 |
| Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients (NCT03787056) | Hospices Civils de Lyon | 2018-12-04 |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies (NCT03999697) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-12-01 |
| A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients (NCT03670888) | JHL Biotech, Inc. | 2018-11-16 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation (NCT03734601) | Stanford University | 2018-11-05 |
| Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma (NCT03478514) | Alliance Foundation Trials, LLC. | 2018-09-11 |
| CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia (NCT03854994) | Yan'an Affiliated Hospital of Kunming Medical University | 2018-08-01 |
| CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies (NCT04156178) | iCell Gene Therapeutics | 2018-08-01 |
| INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) (NCT03424122) | Incyte Corporation | 2018-07-02 |
| CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies (NCT03559439) | Shanghai Tong Ren Hospital | 2018-04-24 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT03448393) | National Cancer Institute (NCI) | 2018-03-26 |
| A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL (NCT03467373) | Hoffmann-La Roche | 2018-03-13 |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (NCT03424603) | Sutro Biopharma, Inc. | 2018-02-22 |
| CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies (NCT04156243) | iCell Gene Therapeutics | 2018-02-01 |
| A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma (NCT03398967) | Chinese PLA General Hospital | 2018-01-02 |
| Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies (NCT03098355) | Zhujiang Hospital | 2017-12-30 |
| Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors (NCT03302403) | Kang YU | 2017-12-29 |
| A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma (NCT03307746) | University Hospital Southampton NHS Foundation Trust | 2017-11-23 |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation (NCT03133221) | University of Maryland, Baltimore | 2017-10-23 |
| Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma (NCT03281551) | Pinze Lifetechnology Co. Ltd. | 2017-10-01 |
| A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma (NCT03166878) | Chinese PLA General Hospital | 2017-06-01 |
| CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. (NCT03146533) | Shenzhen Second People's Hospital | 2017-05-01 |
| A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL (NCT03060850) | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 2017-03-17 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia (NCT03383952) | Immune Cell, Inc. | 2017-03-01 |
| Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma (NCT02898259) | Brian Hill | 2017-02-20 |
| A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients (NCT02945215) | Innovent Biologics (Suzhou) Co. Ltd. | 2016-12-13 |
| BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia (NCT02933320) | Cancer Research UK | 2016-10-27 |
| A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP (NCT02741388) | The Lymphoma Academic Research Organisation | 2016-10-01 |
| Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas (NCT02900716) | Zhejiang DTRM Biopharma | 2016-09-01 |
| The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma (NCT03101709) | Henan Cancer Hospital | 2016-08-01 |
| Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma (NCT02842138) | Peking University | 2016-06-01 |
| CAR T Cells for Refractory B Cell Malignancy (NCT02963038) | Hebei Senlang Biotechnology Inc., Ltd. | 2016-06-01 |
| Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies (NCT03366324) | Wuhan Sian Medical Technology Co., Ltd | 2016-05-01 |
| Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies (NCT03366350) | Wuhan Sian Medical Technology Co., Ltd | 2016-04-15 |
| CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies (NCT02965092) | Wuhan Sian Medical Technology Co., Ltd | 2015-12-02 |
| A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas (NCT02395601) | Constellation Pharmaceuticals | 2015-03-01 |
| Detection and Characterization of Residual Masses in Lymphomas (NCT02300402) | The Lymphoma Academic Research Organisation | 2014-10-01 |
| Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma (NCT02266147) | Dynavax Technologies Corporation | 2014-10-01 |
| Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (NCT02055924) | The Lymphoma Academic Research Organisation | 2014-05-26 |
| CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. (NCT02132624) | Uppsala University | 2014-04-01 |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma (NCT01980628) | Pharmacyclics LLC. | 2013-12-01 |
| Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma (NCT01980654) | Pharmacyclics LLC. | 2013-12-01 |
| Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas (NCT01788189) | University Hospital, Essen | 2013-01-01 |
| Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas (NCT01799083) | Han weidong | 2012-12-01 |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT01647971) | TG Therapeutics, Inc. | 2012-07-19 |
| Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma (NCT01593696) | National Cancer Institute (NCI) | 2012-06-29 |
| Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (NCT01626495) | University of Pennsylvania | 2011-08-17 |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies (NCT00968760) | M.D. Anderson Cancer Center | 2011-06-20 |
| Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma (NCT01148108) | Telik | 2010-06-01 |
| Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia (NCT01109069) | Pharmacyclics LLC. | 2010-06-01 |
| Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (NCT01459653) | Sandoz | 2010-03-01 |
| Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue (NCT01044004) | Washington University School of Medicine | 2010-03-01 |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab (NCT00946023) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2009-07-01 |
| High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas (NCT00895661) | Massachusetts General Hospital | 2009-07-01 |
| Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma (NCT00880867) | Nevada Cancer Institute | 2009-04-01 |